BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 10, 2011
 |  BioCentury  |  Product Development

Bone-free BMP

Thrasos built BMP activators to treat kidney injury, avoid unwanted bone growth

Thrasos Innovation Inc. believes its selective bone morphogenetic protein receptor activators will work for kidney disease because they trigger the BMP pathway's anti-inflammatory, anti-apoptotic and antifibrotic properties, but not its osteogenic properties.

BMP has been in development for kidney disease at least since the mid-'90s. In 1996, Creative BioMolecules Inc., now Curis Inc., presented data showing that bone morphogenetic protein 7 (BMP7; OP-1) protected against kidney damage in animal models of chronic and acute renal failure.

BMP7's beneficial effects in renal disease result from its binding to activin A receptor type I (ACVRI; ALK2) and bone morphogenetic protein receptor type IA (BMPRIA; ALK3), which lead to anti-inflammatory, anti-apoptotic and antifibrotic effects.

But 11 years and two partners later, BMP7 was still in preclinical development.

In 1999, Biogen Idec Inc. declined to exercise an option to...

Read the full 695 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >